BRCA gene mutation

In case of BRCA gene mutation carrier, it is possible to participate in the study because mifepristone contains no estrogen and no progesterone.

There is no reason to assume that mifepristone increases the risk of cancer (in the breast, ovary or uterus).
Of course, researchers can never guarantee that the development of cancer is excluded while using mifepristone.

The Hereditary Cancer Foundation wrote about this research:
"The drug mifepristone would be a very welcome addition to the field of contraception for women from our supporters. It is a tool that our supporters have been waiting for for so long. The Netherlands Hereditary Cancer Foundation will actively bring the research to the attention of its supporters and in the media to increase the chance of a valuable improvement for this group".